-
Medical journals
- Career
Chronic Lymphocytic Leukemia
We recommend
OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?
19. 6. 2024 Source: Chronic Lymphocytic LeukemiaHow to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.
Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for…5. 3. 2024 Source: Chronic Lymphocytic Leukemia
Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?
Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and…7. 12. 2023 Source: Chronic Lymphocytic Leukemia
Articles on this topic
Older patients with CLL and comorbidities: an option for treatment with immunotherapy without chemotherapy?
Is it time to treat chronic lymphocytic leukemia (CLL) without chemotherapy? The authors of a…19. 1. 2021 Source: Chronic Lymphocytic Leukemia
Efficacy of Bruton Tyrosine Kinase Inhibitors After Venetoclax Therapy in Patients with CLL
Targeted therapy has changed the treatment approach for chronic lymphocytic leukemia (CLL),…11. 12. 2020 Source: Chronic Lymphocytic Leukemia
What Next for Patients with CLL After Stopping Venetoclax?
Standard care for untreated patients with chronic lymphocytic leukemia (CLL) is therapy based…17. 7. 2020 Source: Chronic Lymphocytic Leukemia
Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients
A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal…8. 6. 2020 Source: Chronic Lymphocytic Leukemia
Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy
William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro…8. 6. 2020 Source: Chronic Lymphocytic Leukemia
Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs
In the context of the significant advancements in the field of immunotherapy and evidence of…22. 4. 2020 Source: Chronic Lymphocytic Leukemia
Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype
A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic…22. 4. 2020 Source: Chronic Lymphocytic Leukemia
New drugs in CLL may also carry specific risks of adverse effects. How to minimize and manage them?
The possibilities for the treatment of chronic lymphocytic leukemia (CLL) have greatly…13. 3. 2020 Source: Chronic Lymphocytic Leukemia
Journal articles Encyclopedia of CLL Subsets – a Unique Bioinformatics Tool and Database for Analysis of Subsets of Stereotypical B-Cell Receptors in CLL
10. 4. 2019 Source: Clinical Oncology | Supplementum1/2019
Journal articles Chronic lymphocytic leukaemia – contemporary application of modern prognostic and predictive markers in diagnostics
29. 3. 2019 Source: Transfusion and Haematology Today | 1/2019
Journal articles Evolution of chronic lymphocytic leukemia treatment over the past 25 years
Nárůst poznatků o buněčné povaze, patogenezi a genetických změnách chronické lymfocytární leukemie...29. 3. 2019 Source: Transfusion and Haematology Today | 1/2019
1 2Login
Subscribe
E-courses on this topic
Conferences news
Go to records
Go to records
Go to records
18. 1. 2023 - 21. 1. 20231 record
Go to records
27. 5. 2022 - 27. 5. 20221 record
Go to records
Go to records
Go to records
Most read on this topic- Current NCCN Recommendations for CLL/SLL Diagnosis – Version 1.2023
- Venetoclax Treatment Strategies in Patients with CLL
- Chronic lymphocytic leukaemia – contemporary application of modern prognostic and predictive markers in diagnostics
- Evolution of chronic lymphocytic leukemia treatment over the past 25 years
- Current Treatment Options for Refractory/Relapsed CLL
- Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs
Journal on this topic
Related topicLogin#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career